Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
14 December 2023 | Story Dr Jared McDonald | Photo Supplied
Scholarship of Teaching and Learning Conference
From the left: Dr Eleanor Bernard, Assistant Director in the Centre for Teaching and Learning on the UFS Qwaqwa Campus; Dr Jared McDonald, Chief of Staff in the Office of the Vice-Chancellor and Principal; and Prof Pearl Sithole, Campus Vice-Principal: Academic and Research on the Qwaqwa Campus.

From 21 to 23 November, more than 160 delegates gathered at the Golden Gate Highlands National Park in the Eastern Free State for the fourth biennial conference on Scholarship of Teaching and Learning (SOTL) in the South, dubbed SOTL 4 the South.

This year’s iteration was proudly hosted by the University of the Free State (UFS) and organised by Dr Jared McDonald, Chief of Staff in the Office of the Vice-Chancellor and Principal; Dr Eleanor Bernard, Assistant Director in the Centre for Teaching and Learning on the UFS Qwaqwa Campus; and Prof Zach Simpson, Editor-in-Chief of the SOTL in the South journal. Established and emerging scholars, as well as postgraduate students working in the field of teaching and learning from across disciplines in Southern Africa, came together to share ideas, debate perspectives, and learn from experiences related to the conference theme: Teaching and Learning for Sustainable Futures.

The programme included presentations on a wide variety of topics, such as the challenges and opportunities of artificial intelligence in higher education, academic literacy, student success, teaching and learning for sustainable development, curriculum design, and digital futures. The programme also included two keynote presentations by leading scholars in education for sustainability, Prof Heila Lotz-Sisitka, Distinguished Professor and SARChI Research Chair in Global Change and Social Learning Systems in the Environmental Learning Research Centre at Rhodes University, and Prof Kasturi Behari-Leak, Associate Professor of Higher Education Studies and Dean of the University of Cape Town’s Centre for Higher Education Development.

The organisers were delighted with the quality of the scholarship that was shared. “This conference has been 18 months in the making, and we are grateful to all the delegates for embracing, and engaging with, the conference’s theme. We are also appreciative to all the reviewers on the Scientific Review Committee who were generous with their time, reflections, and critiques in assisting us to deliver a compelling, impactful programme,” said Dr McDonald. Dr Bernard added that “the conference would not have been possible without the generous support of the University of the Free State’s Executive Management and Centre for Teaching and Learning, as well as the senior management of the Qwaqwa Campus, who have supported the conference from the time it was just an idea”.

Prof Zach Simpson expressed his gratitude to the UFS for its support and assistance. “The last in-person conference of SOTL in the South was in 2019, before the COVID-19 pandemic. It was wonderful to see so many scholars come together in a beautiful location to engage with a compelling and topical conference theme.” Selected papers have been invited to contribute to a special issue of SOTL in the South, edited by the organisers and due for publication in mid-2024.

SOTL is an informal ‘body’ that is not affiliated with any particular parent organisation or institution. Its aim is to advance scholarship in teaching and learning across the Global South – conceived of not just in geographic terms – but as concerned with questions of power, access, inequity, and marginalisation, even where these might be present in the Global ‘North’. Moreover, it aims to give voice to novice SOTL practitioners and to serve as a platform for academics, particularly novice academics, to contribute their scholarly work.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept